Sentences with phrase «solid tumor malignancies»

Allogeneic cells, particularly mismatched or haploidentical cells, in the context of hematopoietic transplantation have been found to provide potent immune surveillance for both hematologic and solid tumor malignancies in a process referred to as graft - versus - tumor [13]--[15].

Endogenous T cell therapy utilizes naturally - occurring antigen - specific T cells isolated from peripheral blood to treat solid tumor malignancies.

The Phase 1 open - label, multicenter, dose escalation study of mRNA - 2416 is designed to determine the safety and tolerability of escalating iTu doses of mRNA - 2416 in patients with relapsed / refractory solid tumor malignancies or lymphoma, and define the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) and schedule for iTu injections of mRNA - 2416.

Not exact matches

Our pipeline currently includes investigational therapies and next generation technologies for a range of hematologic malignancies and solid tumors.

Only the 91 patients were included in all calculations, including 28 (31 percent) with hematological malignancies and 63 (69 percent) with solid tumors.

He further showed that PD - L1 is highly expressed on many solid tumors such as breast and lung, as well as some hematologic malignancies, and allows these tumors to resist immune attack.

We offer trials for childhood brain tumors, solid tumors, hematological malignancies, infectious diseases, and hematology, including Phase I / II clinical trials.

We are unraveling the mechanisms of this modulation in different solid and hematological malignancies and investigating ways to potentiate iNKT cell control of the tumor microenvironment for cancer immunotherapy.

MLN9708 is also being investigated for treatment of various other hematologic malignancies and solid tumors.

Patients with hematological malignancies are at a particularly higher risk of developing severe infections when compared to other patients with solid tumors and the population in general.

Mutations in IDH1 and IDH2 occur in myeloid malignancies, T - cell lymphomas, and certain solid tumors.

Whether identifying rare subclones missed by standard bulk sequencing, or identifying co-mutation patterns in subclones, Tapestri Single - Cell DNA Panels can be applied across a wide number of applications, including hematologic malignancies, solid tumor profiling, and genome editing programs.

Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion critumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion criTumor type specific exclusion criteria

A class of drugs called EZH2 inhibitors are currently in clinical development for both hematological malignancies and solid tumors and may be effectively targeted to epithelial ovarian cancers overexpressing the CARM1 protein.

«ECHO - 203 is part of the broader ECHO clinical development program investigating efficacy and safety of epacadostat as a core component of combination therapy in a broad range of solid tumor types as well as hematological malignancies,» said Naing.